Tasso, a provider of blood collection solutions, announced the launch of its next generation technology for dried blood spot (DBS) sample collection. The novel collection system combines Tasso’s new Tile-T20 dried whole blood cartridge with a Tasso Mini device, enabling the convenient collection of DBS samples for clinical trials and sports anti-doping testing.
Tasso’s new collection system provides advantages over legacy DBS methods, improving and accelerating the clinical trial process. Tile-T20 is the first DBS collection cartridge designed specifically for use with patient-centric blood lancets. Tile-T20 collects four precise, volumetrically-controlled blood samples that meet the needs of quantitative endpoints or drug concentration measurements. It is compatible with any of Tasso’s virtually painless, FDA-cleared and CE Marked blood collection devices, including Tasso Mini and Tasso+.
Tasso Mini is the latest device in Tasso’s line of blood lancets, providing a gentle collection experience ideal for use with sensitive populations or for applications that may require more frequent blood draws. The Tasso Mini device is FDA Class II Lancet 510(k)-cleared and CE Marked.
“Dried blood samples offer many advantages for clinical trials and remote applications, but collection methods have long been a burden on patients, relying on painful finger sticks and messy blood spotting to obtain samples,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “Our next generation dried blood collection systems enable a better patient experience alongside new process improvements.”
